» Articles » PMID: 6934706

Metabolic Fate of SCE-1365, a New Broad-spectrum Cephalosporin, After Parenteral Administration to Rats and Dogs

Overview
Specialty Pharmacology
Date 1980 Oct 1
PMID 6934706
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Disposition of [14C]SCE-1365 was studied in rats and dogs after intramuscular or intravenous injection. The plasma level of [14C]SCE-1365 peaked at 15 min after intramuscular administration and declined rapidly to give half-lives of 27 and 39 min, respectively, in rats and dogs. After intravenous dosage, half-lives were 22 and 32 min, respectively, in rats and dogs. In both animals, the plasma levels of 14C were made up largely of unchanged antibiotic. Binding to plasma protein was 91 and 31%, respectively, in rats and dogs. Tissue levels of [14C]SCE-1365 administered intramuscularly to rats peaked at 15 min and were highest in the kidney and lowest in the brain, with plasma, liver, lung, heart, intestinal wall, and adrenal gland occupying intermediary positions in the order listed. The concentration of [14C]SCE-1365 in erythrocytes was very low, as was the level of the antibiotic in rat fetuses. The milk of rats given [14C]SCE-1365 intramuscularly contained detectable levels of 14C. [14C]SCE-1365 was completely eliminated from the bodies of rats and dogs within 24 to 48 h. In both animals, a large amount of the dosed 14C was excreted in urine as unaltered antibiotic. The remainder was eliminated in the feces via bile. In rats, [14C]SCE-1365 was eliminated by both glomerular filtration (33%) and tubular secretion (67%). An active transport process appeared to be involved in biliary excretion in rats.

Citing Articles

Changes in the equine fecal microbiota associated with the use of systemic antimicrobial drugs.

Costa M, Stampfli H, Arroyo L, Allen-Vercoe E, Gomes R, Weese J BMC Vet Res. 2015; 11:19.

PMID: 25644524 PMC: 4323147. DOI: 10.1186/s12917-015-0335-7.


Metabolic fate of [14C]SM-1652, a new antipseudomonal cephalosporin, after parenteral administration to rats.

Imasaki H, Enjoji Y, Matsui H, Kawai R, Kawamura S, Okuda T Antimicrob Agents Chemother. 1983; 24(1):42-7.

PMID: 6625556 PMC: 185102. DOI: 10.1128/AAC.24.1.42.


Metabolism of [14C]Cefmenoxime in normal subjects after intramuscular administration.

MACHINIST J, Bopp B, Quinn D Antimicrob Agents Chemother. 1984; 26(4):431-5.

PMID: 6097162 PMC: 179939. DOI: 10.1128/AAC.26.4.431.


Disposition of carumonam (AMA-1080/Ro 17-2301), a new N-sulfonated monocyclic beta-lactam, in rats and dogs.

Yoshida K, Mitani M, Naeshiro I, Torii H, TANAYAMA S Antimicrob Agents Chemother. 1986; 29(6):1017-24.

PMID: 3729358 PMC: 180494. DOI: 10.1128/AAC.29.6.1017.


Disposition of moxalactam and N-methyltetrazolethiol in rats and monkeys.

Mizojiri K, Norikura R, Takashima A, Tanaka H, Yoshimori T, Inazawa K Antimicrob Agents Chemother. 1987; 31(8):1169-76.

PMID: 3631941 PMC: 174898. DOI: 10.1128/AAC.31.8.1169.

References
1.
Matsuzaki M, Matsumoto H, Ochiai K, Tashiro Y, Hino M . [Absorption, distribution and excretion of 14C-cefatrizine (14C-S-640 P) in rat (author's transl)]. Jpn J Antibiot. 1976; 29(4):391-402. View

2.
Klein J, Eickhoff T, Tilles J, FINLAND M . CEPHALOTHIN: ACTIVITY IN VITRO, ABSORPTION AND EXCRETION IN NORMAL SUBJECTS AND CLINICAL OBSERVATIONS IN 40 PATIENTS. Am J Med Sci. 1964; 248:640-56. View

3.
MCCLOSKEY R, Terry E, McCracken A, SWEENEY M, Forland M . Effect of hemodialysis and renal failure on serum and urine concentrations of cephapirin sodium. Antimicrob Agents Chemother. 1972; 1(2):90-3. PMC: 444174. DOI: 10.1128/AAC.1.2.90. View

4.
Kozatani J, Okui M, Noda K, Ogino T, Noguchi H . Cefazolin, a new semisynthetic cephalosporin antibiotic. V. Distribution of cefazolin- 14 C in mice and rats after parenteral administration. Chem Pharm Bull (Tokyo). 1972; 20(6):1105-13. DOI: 10.1248/cpb.20.1105. View

5.
Ochiai M, Aki O, Morimoto A, Okada T, Matsushita Y . New cephalosporin derivatives with high antibacterial activities. Chem Pharm Bull (Tokyo). 1977; 25(11):3115-7. DOI: 10.1248/cpb.25.3115. View